GEN3018 / Genmab - LARVOL DELTA

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Genmab | N=40 ➔ 78

Enrollment change • First-in-human • Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Genmab | N=16 ➔ 40

Enrollment change • First-in-human • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

GCT3018-01: First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrialsregister.eu) - P1 | N=16 | Not yet recruiting | Sponsor: Genmab A/S

First-in-human • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

GCT3018-01: First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrialsregister.eu) - P1 | N=16 | Recruiting | Sponsor: Genmab A/S | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology